These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11006015)

  • 41. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
    Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
    Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo.
    Whiteside TL; Gambotto A; Albers A; Stanson J; Cohen EP
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9415-20. PubMed ID: 12080146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
    Lopes L; Fletcher K; Ikeda Y; Collins M
    Cancer Immunol Immunother; 2006 Aug; 55(8):1011-6. PubMed ID: 16311731
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice.
    Boesen A; Sundar K; Coico R
    Clin Diagn Lab Immunol; 2005 Oct; 12(10):1223-30. PubMed ID: 16210487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
    Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
    Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
    Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
    Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
    Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.
    Cox AL; Skipper J; Chen Y; Henderson RA; Darrow TL; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
    Science; 1994 Apr; 264(5159):716-9. PubMed ID: 7513441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential effect of adenovirus 2 E3/19K glycoprotein on the expression of H-2Kb and H-2Db class I antigens and H-2Kb- and H-2Db-restricted SV40-specific CTL-mediated lysis.
    Tanaka Y; Tevethia SS
    Virology; 1988 Aug; 165(2):357-66. PubMed ID: 2970152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
    McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
    Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
    Shamamian P; Mancini M; Kawakami Y; Restifo NP; Rosenberg SA; Topalian SL
    Cancer Immunol Immunother; 1994 Aug; 39(2):73-83. PubMed ID: 7519127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    Paglia P; Chiodoni C; Rodolfo M; Colombo MP
    J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
    Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.
    Sugita S; Sagawa K; Mochizuki M; Shichijo S; Itoh K
    Int Immunol; 1996 May; 8(5):799-803. PubMed ID: 8671669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytotoxic T lymphocytes from HLA-A2 transgenic mice specific for HLA-A2 expressed on human cells.
    Bernhard EJ; Le AX; Barbosa JA; Lacy E; Engelhard VH
    J Exp Med; 1988 Sep; 168(3):1157-62. PubMed ID: 3262704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line.
    Santegoets SJ; Schreurs MW; Masterson AJ; Liu YP; Goletz S; Baumeister H; Kueter EW; Lougheed SM; van den Eertwegh AJ; Scheper RJ; Hooijberg E; de Gruijl TD
    Cancer Immunol Immunother; 2006 Dec; 55(12):1480-90. PubMed ID: 16468034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.
    Hayashi Y; Hoon DS; Foshag LJ; Park MS; Terasaki PI; Morton DL
    Cancer; 1993 Aug; 72(3):750-9. PubMed ID: 8334627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
    Pouw N; Treffers-Westerlaken E; Kraan J; Wittink F; ten Hagen T; Verweij J; Debets R
    Cancer Immunol Immunother; 2010 Jun; 59(6):921-31. PubMed ID: 20101507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficient induction of antitumor cytotoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro.
    Tanaka F; Fujie T; Go H; Baba K; Mori M; Takesako K; Akiyoshi T
    Cancer Immunol Immunother; 1997 Mar; 44(1):21-6. PubMed ID: 9111580
    [TBL] [Abstract][Full Text] [Related]  

  • 60. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.
    Skoberne M; Yewdall A; Bahjat KS; Godefroy E; Lauer P; Lemmens E; Liu W; Luckett W; Leong M; Dubensky TW; Brockstedt DG; Bhardwaj N
    J Clin Invest; 2008 Dec; 118(12):3990-4001. PubMed ID: 19033668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.